HopeStage
Back to all studies
CompletedNCT00218465

GW468816 compared with placebo to prevent smoking relapse in women

About this titleRead the official source — NCT00218465
Medication studyAges 18–65United StatesAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
Belmont and 1 more locationSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateAugust 2006
Recruitment status
Completed
Enrollment listed in the registry
264
Sponsor
Massachusetts General Hospital
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT00218465
Official title
Show the full official title

A Double-Blind, Placebo-Controlled Trial of the NMDA Glycine Site Antagonist, GW468816, for Prevention of Relapse to Smoking

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Belmont · Boston

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including GW468816 and Placebo Comparator: Placebo.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies